Literature DB >> 21808583

Valethamate bromide: Is there any proof of efficacy and safety for its use in labor?

B Gitanjali1.   

Abstract

Entities:  

Year:  2010        PMID: 21808583      PMCID: PMC3142753          DOI: 10.4103/0976-500X.64528

Source DB:  PubMed          Journal:  J Pharmacol Pharmacother        ISSN: 0976-500X


× No keyword cloud information.
It has often been said that medicine is an art based on conjecture and improved by murder. Valethamate bromide is a drug widely used all over India by obstetricians for facilitating cervical dilatation in the first stage of labor.[1] It is sold under many brand names such as Epidosin, Dilaton, Valosin, Valamate, Osdil etc. Even though this drug is available in India for more than a quarter of a century, it is still not listed in the Indian Pharmacopoeia. None of the well established textbooks of pharmacology from North America and the United Kingdom mention the drug, though one popular textbook from India makes a mention.[2] Reliable sources of information like the British National Formulary also do not list it. A Google Scholar search on the term produces ten hits and a PubMed search on the molecule throws up just seven articles with only two clinical trials published in peer reviewed indexed journals. This seems to be the total quantity of information from the web sources. Yet, it is listed in the Tamil Nadu Medical Services Corporation procurement list as the item with the drug code 460.[3] This raises an interesting question. How and why is this drug so popular when there is so little information of its safety and efficacy? It is obvious that the drug is being used mainly due to three reasons. First, cervical ripening and dilatation is a natural feature of labor and using drugs to hasten the process may be beneficial in crowded labor rooms to facilitate the reduction in time spent in monitoring women in labor rather than any sound medical reason. Second, there are also no “new” drugs for this indication since evaluating drugs in pregnant women has its own share of problems and ethical concerns. Therefore, continuing to use something which was introduced when the criteria for using drugs were less stringent is easy. Third, the promotional pressures from the pharmaceutical companies are relentless. Obstetricians may be duped to believe that they are indeed using a drug which is listed in the Indian Pharmacopoeia (I.P.) The carton of Epidosin lists three ingredients on it [Figure 1]. One is valethamate bromide and the other two are normal saline and water for injection. It is interesting to note that both saline and water have I.P. listed next to their names. What is missed by the undiscerning mind is that there is no I.P next to valethamate bromide. This is perhaps why many practicing obstetricians have failed to question the very basis for the use of this drug. Is it efficacious? There are no studies which prove it, and the meagre data shows that it is ineffective.[45] One study which mentions that valethamate is as effective as drotavarine[6] is an unblinded, underpowered trial which has used inappropriate statistical tests for data analysis, while another study comparing the same drugs says it is less efficacious than drotavarine but has more side effects.[7]
Figure 1

A photograph of the carton of Epidosin (valethamate bromide)

A photograph of the carton of Epidosin (valethamate bromide) Is it safe? Not really, since two studies have recorded adverse events of moderate intensity[4 5] and one study noted mild events.[7] This brings us to the question, whether it should be used in pregnant women at all since both the efficacy and safety have not been adequately documented. The answer to this question can only be an emphatic “no”. The World Health Organization (WHO) has brought out guidelines outlining the criteria for the selection of drugs for any indication and valethamate bromide does not satisfy even one of them. It is hoped that obstetricians will stop using this drug in pregnant women until there is convincing evidence of its efficacy and safety and it is listed in the Indian Pharmacopoeia. Essential medicine lists and procurement lists should not list this drug which does not have the evidence to support its continued use in pregnant women.
  4 in total

1.  A randomized controlled trial of valethamate bromide in acceleration of labor.

Authors:  S Kuruvila; P Jasper; A Peedicayil; M Mathai
Journal:  Int J Gynaecol Obstet       Date:  1992-06       Impact factor: 3.561

2.  Meperidine versus valethamate bromide in shortening the duration of active labor.

Authors:  Bulent Yilmaz; Cavit Kart; Sefa Kelekci; Umut Gokturk; Necdet Sut; Nurten Tarlan; Leyla Mollamahmutoglu
Journal:  Int J Gynaecol Obstet       Date:  2009-08-06       Impact factor: 3.561

3.  Drotaverine hydrochloride vs. valethamate bromide in acceleration of labor.

Authors:  J B Sharma; P Pundir; A Kumar; N S Murthy
Journal:  Int J Gynaecol Obstet       Date:  2001-09       Impact factor: 3.561

4.  A randomised controlled study comparing Drotaverine hydrochloride and Valethamate bromide in the augmentation of labour.

Authors:  Chendrimada Madhu; Suvarna Mahavarkar; Sudhir Bhave
Journal:  Arch Gynecol Obstet       Date:  2009-07-31       Impact factor: 2.344

  4 in total
  3 in total

Review 1.  Antispasmodics for labour.

Authors:  Anke C Rohwer; Oswell Khondowe; Taryn Young
Journal:  Cochrane Database Syst Rev       Date:  2013-06-05

2.  Valethamate bromide: Conflicting evidence and continuing use.

Authors:  Thirunavukkarasu Arun Babu; Vijayan Sharmila
Journal:  J Pharmacol Pharmacother       Date:  2010-07

3.  Author's reply.

Authors:  B Gitanjali
Journal:  J Pharmacol Pharmacother       Date:  2010-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.